Payment overview · 2025
General Payments
$552.63
21 reported records · 7 companies
Healthcare provider profile · identity verified
Albert Klemptner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · YPSILANTI, MI · NPI 1952396129
Verified facts
What the public records show
CMS Open Payments records show Albert Klemptner, MD received $552.63 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 358 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $211.02 | 38.2% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.41 | 25.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.77 | 16.8% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $42.98 | 7.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.31 | 5.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.31 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.83 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $552.63 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $120.66 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.77 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $56.81 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.29 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| SEROQUEL Normalized: seroquel |
Drug | AstraZeneca Pharmaceuticals LP | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 170 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
358 | 358 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 928 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 750 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 642 | 147 |
| Omeprazole | Omeprazole | 500 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 463 | 111 |
| Prednisone | Prednisone | 423 | 175 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 358 | 358 |
| Metformin Hcl | Metformin Hcl | 294 | 71 |
| Azithromycin | Azithromycin | 285 | 135 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 70 |
| Losartan Potassium | Losartan Potassium | 265 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 262 | 82 |
| Lisinopril | Lisinopril | 239 | 64 |
| Simvastatin | Simvastatin | 219 | 50 |
| Furosemide | Furosemide | 210 | 67 |
| Montelukast Sodium | Montelukast Sodium | 209 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 56 |
| Trazodone Hcl | Trazodone Hcl | 188 | 46 |
| Gabapentin | Gabapentin | 183 | 34 |
| Eliquis | Apixaban | 170 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 135 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 30 |
| Alprazolam | Alprazolam | 133 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 25 |
| Amoxicillin | Amoxicillin | 131 | 63 |
| Potassium Chloride | Potassium Chloride | 131 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 120 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 31 |
| Carvedilol | Carvedilol | 117 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 31 |
| Ibuprofen | Ibuprofen | 113 | 32 |
| Finasteride | Finasteride | 110 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 22 |
| Buspirone Hcl | Buspirone Hcl | 94 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 84 | 28 |
| Pregabalin | Pregabalin | 84 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 35 |
| Sertraline Hcl | Sertraline Hcl | 73 | 21 |
| Nateglinide | Nateglinide | 72 | 15 |
| Glimepiride | Glimepiride | 70 | 17 |
| Ezetimibe | Ezetimibe | 67 | suppressed |
| Januvia | Sitagliptin Phosphate | 65 | 19 |
| Spironolactone | Spironolactone | 57 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 14 |
| Famotidine | Famotidine | 50 | 17 |
| Donepezil Hcl | Donepezil Hcl | 49 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 13 |
| Atenolol | Atenolol | 46 | suppressed |
| Lorazepam | Lorazepam | 46 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 25 |
| Allopurinol | Allopurinol | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Nystatin | Nystatin | 41 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 13 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 24 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Lactulose | Lactulose | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 14 |
| Latanoprost | Latanoprost | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $552.63 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, ELIQUIS, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SEROQUEL, TRELEGY ELLIPTA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error